Skip to content
(614)355-5560
October 12, 2023
Respiratory Syncytial Virus (RSV) Prevention Resource

Update: Due to increased supply of nirsevimab, the Centers for Disease Control and Prevention (CDC) recommends returning to the original guidance set forth by the CDC and ACIP for use of nirsevimab in young children. To read the full announcement please click here. Additional guidance for RSV-prevention, including recommendations for the maternal RSV-vaccine, is now available within the CDC’s immunization schedule.

Background

Respiratory syncytial virus (RSV) is a common cause of respiratory illness in children and is the most common cause of hospitalization in infants. On July 17th, 2023 the FDA approved nirsevimab (BeyfortusTM), a monoclonal antibody indicated for the prevention of severe RSV for infants and select high risk children. On August 3rd, The Advisory Committee on Immunization Practices (ACIP) unanimously recommended the addition of nirsevimab to the Centers for Disease Control and Prevention’s (CDC’s) child immunization schedule and Vaccines for Children (VFC) program. The CDC recommends one dose of nirsevimab for all infants younger than 8 months, born during or entering their first RSV season. Additionally, it is recommended for children 8 to 19 months old who are at increased risk for severe RSV disease during their 2nd RSV season. Partners For Kids will update this page when new information and resources become available.

Partners For Kids Communication

Here you will find Partners For Kids developed content around RSV prevention, including
newsletter updates and webinars.

For Healthcare Professionals

This section contains links to reputable sources of information for health care professionals to learn more about nirsevimab and RSV-prevention.

For Patients

These links are to patient facing websites and material that help to explain the importance of RSV-prevention and the recommendations for using nirsevimab.

 

Related Articles
Pharmacy Updates
April 3, 2024
Quarterly Update for Partners For Kids Pediatric-Focused Unified Preferred Drug List (UPDL)
Read More
Pharmacy Updates
April 3, 2024
Quarterly Update for Partners For Kids Pediatric-Focused Unified Preferred Drug List (UPDL)
Read More
Pharmacy Updates
March 5, 2024
Updated Attention Deficit Hyperactivity Disorder (ADHD) Guidelines are Now Available – Central Region
Resources within the guideline include screening tools, treatment algorithms, and medication dosing recommendations.
Read More
Pharmacy Updates
March 5, 2024
A New Tool to Overcome Access Barriers to Spacer-Compatible Inhaled Steroids
Partners For Kids has created a pathway to guide decision-making when prescribing inhaled steroids for children.
Read More
Pharmacy Updates
March 5, 2024
A New Tool to Overcome Access Barriers to Spacer-Compatible Inhaled Steroids
Partners For Kids has created a pathway to guide decision-making when prescribing inhaled steroids for children. 
Read More
Pharmacy Updates
February 15, 2024
Updated Nicotine Dependence Prescribing Guidelines Now Available
Topics include screening and diagnostic tools, first-line behavioral modifications and external support, recommended medication and nicotine replacement therapies, and treatment time frame recommendations.
Read More